-
1
-
-
4444288689
-
Prevalence and treatment of spasticity reported by multiple sclerosis patients
-
Rizzo M.A., Hadjimichael O.C., Preiningerova J., Vollmer T.L. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004, 10:589-595.
-
(2004)
Mult Scler
, vol.10
, pp. 589-595
-
-
Rizzo, M.A.1
Hadjimichael, O.C.2
Preiningerova, J.3
Vollmer, T.L.4
-
2
-
-
84878024159
-
Spasticity in multiple sclerosis: Results of a patient survey
-
Oreja-Guevara C., González-Segura D., Vila C. Spasticity in multiple sclerosis: Results of a patient survey. Int J Neurosci 2013, 123:400-408.
-
(2013)
Int J Neurosci
, vol.123
, pp. 400-408
-
-
Oreja-Guevara, C.1
González-Segura, D.2
Vila, C.3
-
3
-
-
84862895347
-
Spasticity and everyday life in multiple sclerosis
-
Donzé C., De Sèze J. Spasticity and everyday life in multiple sclerosis. Rev Neurol (Paris) 2012, 168:S51-S56.
-
(2012)
Rev Neurol (Paris)
, vol.168
-
-
Donzé, C.1
De Sèze, J.2
-
4
-
-
0346733218
-
Treatments for spasticity and pain in multiple sclerosis: A systematic review
-
Beard S., Hunn A., Wight J. Treatments for spasticity and pain in multiple sclerosis: A systematic review. Health Technol Assess 2003, 7:1-111.
-
(2003)
Health Technol Assess
, vol.7
, pp. 1-111
-
-
Beard, S.1
Hunn, A.2
Wight, J.3
-
6
-
-
52949104790
-
The endocannabinoid system and multiple sclerosis
-
Baker D., Pryce G. The endocannabinoid system and multiple sclerosis. Curr Pharm Des 2008, 14:2326-2336.
-
(2008)
Curr Pharm Des
, vol.14
, pp. 2326-2336
-
-
Baker, D.1
Pryce, G.2
-
7
-
-
21644439772
-
The role of cannabinoid system on immune modulation: Therapeutic implications on CNS inflammation
-
Correa F., Mestre L., Molina-Holgado E., Arévalo-Martín A., Docagne F., Romero E., et al. The role of cannabinoid system on immune modulation: Therapeutic implications on CNS inflammation. Mini Rev Med Chem 2005, 5:671-675.
-
(2005)
Mini Rev Med Chem
, vol.5
, pp. 671-675
-
-
Correa, F.1
Mestre, L.2
Molina-Holgado, E.3
Arévalo-Martín, A.4
Docagne, F.5
Romero, E.6
-
8
-
-
84901678851
-
-
Ficha técnica Sativex® (delta-9-tetrahidrocannabinol/cannabidiol) [consultado 1 Feb 2013]. European Medicines Agency. Disponible en:
-
Ficha técnica Sativex® (delta-9-tetrahidrocannabinol/cannabidiol) [consultado 1 Feb 2013]. European Medicines Agency. Disponible en: http://www.aemps.gob.es/cima/especialidad.do%3Fmetodo=verFichaWordPdf%26codigo=72544%26formato=pdf%26formulario=FICHAS%26file=ficha.pdf.
-
-
-
-
9
-
-
84867255279
-
Tratamiento de la espasticidad en la esclerosis múltiple: nuevas perspectivas con el uso de cannabinoides
-
Oreja-Guevara C. Tratamiento de la espasticidad en la esclerosis múltiple: nuevas perspectivas con el uso de cannabinoides. Rev Neurol 2012, 55:421-430.
-
(2012)
Rev Neurol
, vol.55
, pp. 421-430
-
-
Oreja-Guevara, C.1
-
10
-
-
79953822342
-
®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
-
Sativex Spasticity Study Group
-
®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011, 18:1122-1131. Sativex Spasticity Study Group.
-
(2011)
Eur J Neurol
, vol.18
, pp. 1122-1131
-
-
Novotna, A.1
Mares, J.2
Ratcliffe, S.3
Novakova, I.4
Vachova, M.5
Zapletalova, O.6
-
11
-
-
68649086665
-
A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis
-
Anwar K., Barnes M.P. A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. Neurorehabilitation 2009, 24:333-340.
-
(2009)
Neurorehabilitation
, vol.24
, pp. 333-340
-
-
Anwar, K.1
Barnes, M.P.2
-
12
-
-
0023130157
-
Interrater reliability of a modified Ashworth scale of muscle spasticity
-
Bohannon R.W., Smith M.B. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987, 67:206-207.
-
(1987)
Phys Ther
, vol.67
, pp. 206-207
-
-
Bohannon, R.W.1
Smith, M.B.2
-
13
-
-
73449143839
-
Stop using the Ashworth Scale for the assessment of spasticity
-
Fleuren J.F., Voerman G.E., Erren-Wolters C.V., Snoek G.J., Rietman J.S., Hermens H.J., et al. Stop using the Ashworth Scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry 2010, 81:46-52.
-
(2010)
J Neurol Neurosurg Psychiatry
, vol.81
, pp. 46-52
-
-
Fleuren, J.F.1
Voerman, G.E.2
Erren-Wolters, C.V.3
Snoek, G.J.4
Rietman, J.S.5
Hermens, H.J.6
-
14
-
-
84856757851
-
A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)
-
Notcutt W., Langford R., Davies P., Ratcliffe S., Potts R. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). Mult Scler 2012, 18:219-228.
-
(2012)
Mult Scler
, vol.18
, pp. 219-228
-
-
Notcutt, W.1
Langford, R.2
Davies, P.3
Ratcliffe, S.4
Potts, R.5
|